These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14645649)

  • 1. Enfuvirtide for prophylaxis against HIV infection.
    Cuzin L; Alvarez M
    N Engl J Med; 2003 Nov; 349(22):2169-70; author reply 2169-70. PubMed ID: 14645649
    [No Abstract]   [Full Text] [Related]  

  • 2. Enfuvirtide for prophylaxis against HIV Infection.
    Ferranti S; Menichetti F
    N Engl J Med; 2003 Aug; 349(8):815. PubMed ID: 12930939
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 4. Fusion inhibition--a major but costly step forward in the treatment of HIV-1.
    Tashima KT; Carpenter CC
    N Engl J Med; 2003 May; 348(22):2249-50. PubMed ID: 12773653
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV infection--a new drug and new costs.
    Steinbrook R
    N Engl J Med; 2003 May; 348(22):2171-2. PubMed ID: 12773643
    [No Abstract]   [Full Text] [Related]  

  • 6. ConFuzeon reigns.
    Huff B
    GMHC Treat Issues; 2003 Apr; 17(4):10. PubMed ID: 12751446
    [No Abstract]   [Full Text] [Related]  

  • 7. Enfuvirtide (Fuzeon): the first fusion inhibitor.
    Williams IG
    Int J Clin Pract; 2003 Dec; 57(10):890-7. PubMed ID: 14712892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. US FDA approves new class of HIV therapeutics.
    Robertson D
    Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
    [No Abstract]   [Full Text] [Related]  

  • 9. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.
    Sax PE; Losina E; Weinstein MC; Paltiel AD; Goldie SJ; Muccio TM; Kimmel AD; Zhang H; Freedberg KA; Walensky RP
    J Acquir Immune Defic Syndr; 2005 May; 39(1):69-77. PubMed ID: 15851916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen.
    Cohan D; Feakins C; Wara D; Petru A; McNicholl I; Schillinger D; Lu J; Kuritzkes D; Deeks SG
    AIDS; 2005 Jun; 19(9):989-90. PubMed ID: 15905684
    [No Abstract]   [Full Text] [Related]  

  • 12. Enfuvirtide approved for defusing HIV.
    Burton A
    Lancet Infect Dis; 2003 May; 3(5):260. PubMed ID: 12726955
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.
    Hornberger J; Kilby JM; Wintfeld N; Green J
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):240-7. PubMed ID: 16545010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfuvirtide, a new drug for HIV infection.
    Fletcher CV
    Lancet; 2003 May; 361(9369):1577-8. PubMed ID: 12747873
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy.
    Hornberger J; Green J; Wintfeld N; Cavassini M; Rockstroh J; Giuliani G; De Carli C; Lazzarin A
    HIV Clin Trials; 2005; 6(2):92-102. PubMed ID: 15983893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
    Pham PA
    Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
    [No Abstract]   [Full Text] [Related]  

  • 17. [Enfuvirtide, mechanism of action and pharmacological properties].
    Kapić E; Becić F; Zvizdić S
    Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
    Morse C; Maldarelli F
    J Infect Dis; 2007 Feb; 195(3):318-21. PubMed ID: 17205468
    [No Abstract]   [Full Text] [Related]  

  • 19. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough.
    Meyohas MC; Lacombe K; Carbonne B; Morand-Joubert L; Girard PM
    AIDS; 2004 Sep; 18(14):1966-8. PubMed ID: 15353987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.